Source comparison
Head-to-Head vs. Cross-Trial: The Only Fair Comparisons
This is the section that keeps the rest honest. There is no study in which PT-141 and Melanotan II were administered to comparable subjects and measured against each other — not in humans, and not even in the same animal model. Any statement that one is “stron
This comparison does not assign a generated winner or score.
- This is the section that keeps the rest honest. There is no study in which PT-141 and Melanotan II were administered to comparable subjects and measured against each other — not in humans, and not even in the same animal model. Any statement that one is “stronger,” “safer,” or “better” is cross-trial inference: it stitches together numbers from separate studies run years apart in different people, which cannot establish superiority because population, dose, assay, and design all confound the read. What can be said fairly is narrow: PT-141 has adequately powered human RCTs and an approval; Melanotan II has small early crossover studies and a harm-dominated modern literature. The evidence-grading table below makes each reported role explicit.
- PT-141 improves sexual desire/distress in premenopausal HSDD
- Two Phase 3 RCTs (RECONNECT) + Phase 2b RCT[1][2]
- Well supported for that specific population/endpoint; the basis of its FDA approval — effect is real but modest
- PT-141 produces erection in men with ED
- Phase 1/2 clinical studies[3]
- Demonstrated short-term effect; the male-ED program was discontinued, not approved
- Melanotan II produces erection/desire in men with ED
- Small double-blind crossover study (n≈20)[4]
- Real early signal; hypothesis-generating; development discontinued, never approved
- Melanotan II for tanning (its dominant use)
- No efficacy/safety trial; case reports of harm[6][9]
- Not established as safe; associated with melanocytic changes and national warnings
- PT-141 “beats” Melanotan II (or vice versa)
- No head-to-head trial
- Cannot be claimed from the evidence; cross-trial inference only
- Either peptide for a shared, directly comparable endpoint
- No direct comparison exists
- The approved use (female HSDD) and MT-2’s dominant use (tanning) do not even overlap
- Notice a subtlety the table exposes: even the “same” effect — the central sexual effect — was studied in different populations (women with HSDD for PT-141; men with ED for both PT-141 and Melanotan II), so a clean apples-to-apples read is impossible. And the two compounds’ dominant real-world uses — approved female HSDD versus off-label male tanning-and-libido — barely intersect, which makes any “which is better” framing a category error before the evidence is even weighed.